Which has higher valuation and earnings, DMAC or CGTX?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.71 N/A Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A

Is DMAC or CGTX more profitable?

Cognition Therapeutics' return on equity of -72.68% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.15% -69.23% Cognition Therapeutics N/A -72.68% -53.07%

Does the media prefer DMAC or CGTX?

In the previous week, Cognition Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Cognition Therapeutics and 3 mentions for DiaMedica Therapeutics. Cognition Therapeutics' average media sentiment score of 0.97 beat DiaMedica Therapeutics' score of 0.63 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, CGTX or TENX?

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A Tenax Therapeutics N/A N/A -$52.60M -$1.40 N/A

Is CGTX or TENX more profitable?

Tenax Therapeutics' return on equity of -56.32% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Tenax Therapeutics N/A -56.32% -53.12%

Does the media favor CGTX or TENX?

In the previous week, Tenax Therapeutics had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for Tenax Therapeutics and 4 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.97 beat Tenax Therapeutics' score of 0.47 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenax Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CGTX or CMPX more profitable?

Compass Therapeutics' return on equity of -39.75% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Compass Therapeutics N/A -39.75% -35.29%

Do analysts prefer CGTX or AVIR?

Cognition Therapeutics presently has a consensus target price of $3.33, indicating a potential upside of 230.03%. Given Cognition Therapeutics' higher possible upside, equities analysts clearly believe Cognition Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, CGTX or AVIR?

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is CGTX or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Atea Pharmaceuticals N/A -57.01% -51.49%

Does the media favor CGTX or AVIR?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Cognition Therapeutics and 2 mentions for Atea Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.97 beat Atea Pharmaceuticals' score of 0.94 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cognition Therapeutics (CGTX) Competitors

$1.01 -0.01 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$1.00 -0.01 (-1.09%)

As of 07:56 PM Eastern

Compare

CGTX vs. DMAC, TENX, CMPX, UPB, and AVIR

Should you buy Cognition Therapeutics stock or one of its competitors? MarketBeat compares Cognition Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cognition Therapeutics include DiaMedica Therapeutics (DMAC), Tenax Therapeutics (TENX), Compass Therapeutics (CMPX), Upstream Bio (UPB), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.

How does Cognition Therapeutics compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

DiaMedica Therapeutics currently has a consensus price target of $12.33, indicating a potential upside of 65.99%. Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 230.03%. Given Cognition Therapeutics' higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cognition Therapeutics' return on equity of -72.68% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.15%	-69.23%
Cognition Therapeutics	N/A	-72.68%	-53.07%

DiaMedica Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

In the previous week, Cognition Therapeutics had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 4 mentions for Cognition Therapeutics and 3 mentions for DiaMedica Therapeutics. Cognition Therapeutics' average media sentiment score of 0.97 beat DiaMedica Therapeutics' score of 0.63 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.71	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Summary

Cognition Therapeutics beats DiaMedica Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Cognition Therapeutics compare to Tenax Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Tenax Therapeutics' return on equity of -56.32% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Tenax Therapeutics	N/A	-56.32%	-53.12%

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 230.03%. Tenax Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 144.22%. Given Cognition Therapeutics' higher probable upside, equities research analysts plainly believe Cognition Therapeutics is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Tenax Therapeutics had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 6 mentions for Tenax Therapeutics and 4 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.97 beat Tenax Therapeutics' score of 0.47 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenax Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cognition Therapeutics has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.40	N/A

Summary

Cognition Therapeutics beats Tenax Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cognition Therapeutics compare to Compass Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Cognition Therapeutics has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Compass Therapeutics	$850K	464.00	-$66.49M	-$0.41	N/A

Compass Therapeutics' return on equity of -39.75% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Compass Therapeutics	N/A	-39.75%	-35.29%

Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

In the previous week, Cognition Therapeutics had 3 more articles in the media than Compass Therapeutics. MarketBeat recorded 4 mentions for Cognition Therapeutics and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.87 beat Cognition Therapeutics' score of 0.97 indicating that Compass Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Compass Therapeutics	Very Positive

Cognition Therapeutics currently has a consensus price target of $3.33, suggesting a potential upside of 230.03%. Compass Therapeutics has a consensus price target of $12.25, suggesting a potential upside of 459.36%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Compass Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Compass Therapeutics beats Cognition Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Upstream Bio?

Cognition Therapeutics (NASDAQ:CGTX) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

In the previous week, Cognition Therapeutics had 3 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Cognition Therapeutics and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.44 beat Cognition Therapeutics' score of 0.97 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Cognition Therapeutics	Positive
Upstream Bio	Positive

Cognition Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Cognition Therapeutics has higher earnings, but lower revenue than Upstream Bio. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Upstream Bio	$2.85M	136.34	-$143.44M	-$2.91	N/A

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 16.5% of Upstream Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cognition Therapeutics presently has a consensus target price of $3.33, suggesting a potential upside of 230.03%. Upstream Bio has a consensus target price of $33.17, suggesting a potential upside of 364.52%. Given Upstream Bio's higher possible upside, analysts clearly believe Upstream Bio is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Cognition Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Summary

Upstream Bio beats Cognition Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cognition Therapeutics compare to Atea Pharmaceuticals?

Cognition Therapeutics (NASDAQ:CGTX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Cognition Therapeutics presently has a consensus target price of $3.33, indicating a potential upside of 230.03%. Given Cognition Therapeutics' higher possible upside, equities analysts clearly believe Cognition Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Atea Pharmaceuticals' return on equity of -57.01% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

In the previous week, Cognition Therapeutics had 2 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Cognition Therapeutics and 2 mentions for Atea Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.97 beat Atea Pharmaceuticals' score of 0.94 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cognition Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cognition Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Summary

Cognition Therapeutics beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Cognition Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGTX vs. The Competition

Export

Metric	Cognition Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$91.29M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.43%
P/E Ratio	-4.21	20.98	27.04	24.38
Price / Sales	N/A	311.16	524.25	93.48
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	2.59	8.54	10.80	6.33
Net Income	-$23.49M	$23.83M	$3.59B	$331.02M
7 Day Performance	-6.48%	-3.53%	-2.24%	-1.09%
1 Month Performance	-16.53%	6.29%	3.12%	-0.49%
1 Year Performance	66.94%	48.64%	26.30%	19.90%

Cognition Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGTX Cognition Therapeutics	4.0906 of 5 stars	$1.01 -1.0%	$3.33 +230.0%	+79.8%	$91.29M	N/A	N/A	20	News Coverage
DMAC DiaMedica Therapeutics	1.3684 of 5 stars	$7.62 flat	$12.33 +61.9%	+106.3%	$410.59M	N/A	N/A	20	News Coverage
TENX Tenax Therapeutics	3.3281 of 5 stars	$15.46 flat	$38.00 +145.8%	+173.9%	$410.08M	N/A	N/A	9	News Coverage Short Interest Increase High Trading Volume
CMPX Compass Therapeutics	2.9916 of 5 stars	$2.27 flat	$12.25 +439.6%	-16.3%	$408.80M	$850K	N/A	20
UPB Upstream Bio	2.2718 of 5 stars	$7.51 flat	$33.17 +341.6%	-36.6%	$408.69M	$2.85M	N/A	38	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGTX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cognition Therapeutics (CGTX) Competitors

CGTX vs. DMAC, TENX, CMPX, UPB, and AVIR

How does Cognition Therapeutics compare to DiaMedica Therapeutics?

Summary

How does Cognition Therapeutics compare to Tenax Therapeutics?

Summary

How does Cognition Therapeutics compare to Compass Therapeutics?

Summary

How does Cognition Therapeutics compare to Upstream Bio?

Summary

How does Cognition Therapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cognition Therapeutics (CGTX) Competitors

CGTX vs. DMAC, TENX, CMPX, UPB, and AVIR

How does Cognition Therapeutics compare to DiaMedica Therapeutics?

Do analysts recommend DMAC or CGTX?

Is DMAC or CGTX more profitable?

Which has more risk & volatility, DMAC or CGTX?

Does the media prefer DMAC or CGTX?

Do insiders and institutionals believe in DMAC or CGTX?

Which has higher valuation and earnings, DMAC or CGTX?

Summary

How does Cognition Therapeutics compare to Tenax Therapeutics?

Is CGTX or TENX more profitable?

Do analysts rate CGTX or TENX?

Does the media favor CGTX or TENX?

Which has more risk & volatility, CGTX or TENX?

Do insiders & institutionals hold more shares of CGTX or TENX?

Which has stronger valuation & earnings, CGTX or TENX?

Summary

How does Cognition Therapeutics compare to Compass Therapeutics?

Which has preferable earnings and valuation, CGTX or CMPX?

Is CGTX or CMPX more profitable?

Which has more risk and volatility, CGTX or CMPX?

Does the media favor CGTX or CMPX?

Do analysts prefer CGTX or CMPX?

Do institutionals and insiders hold more shares of CGTX or CMPX?

Summary

How does Cognition Therapeutics compare to Upstream Bio?

Does the media favor CGTX or UPB?

Which has more risk & volatility, CGTX or UPB?

Which has stronger valuation and earnings, CGTX or UPB?

Do insiders and institutionals hold more shares of CGTX or UPB?

Do analysts prefer CGTX or UPB?

Is CGTX or UPB more profitable?

Summary

How does Cognition Therapeutics compare to Atea Pharmaceuticals?

Do analysts prefer CGTX or AVIR?

Is CGTX or AVIR more profitable?

Does the media favor CGTX or AVIR?

Which has higher valuation and earnings, CGTX or AVIR?

Do institutionals and insiders believe in CGTX or AVIR?

Which has more risk and volatility, CGTX or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGTX vs. The Competition

Cognition Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools